Our evidence that mutations in BRCA1/2 and CHEK2 predispose Polish women to DCIS, should encourage clinicians to refer patients with DCIS for genetic counselling and testing more commonly. This evidence concerns the gene CHEK2 and ductal breast carcinoma in situ.